rs1801252 — ADRB1 Ser49Gly

Beta-1 adrenergic receptor variant at position 49 affecting receptor downregulation kinetics, resting heart rate, heart failure prognosis, and endurance exercise capacity

See your personal result for ADRB1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ADRB1 Ser49Gly — Your Heart's Idle Speed

The ADRB1 gene encodes the beta-1 adrenergic receptor11 beta-1 adrenergic receptor
The primary catecholamine receptor on cardiac muscle cells, controlling heart rate, contractile force, and cardiac output in response to stress and exercise, the heart's main throttle for sympathetic nervous system signaling. While the Arg389Gly variant (rs1801253) controls how strongly the receptor fires when activated, the Ser49Gly variant at position 49 determines how quickly the receptor is pulled off the cell surface and degraded during sustained catecholamine exposure — a process called agonist-promoted downregulation22 agonist-promoted downregulation
The cell actively removes and destroys receptors from its surface during prolonged stimulation, reducing the signal over time — a built-in brake on excessive activation.

At codon 49, the common A allele encodes serine (Ser49), while the minor G allele encodes glycine (Gly49). About 75% of people worldwide are Ser49 homozygotes; only ~2% carry two copies of the Gly49 allele. Despite its lower frequency, the Gly49 variant has outsized importance: it produces a receptor that shuts itself down faster under stress, lowers resting heart rate by approximately 5 bpm, protects against heart failure mortality, and is overrepresented among endurance athletes.

The Mechanism

The Ser49Gly substitution sits in the extracellular N-terminal domain of the receptor, altering its N-glycosylation33 N-glycosylation
The addition of sugar chains to the protein, which affects how the receptor is processed, folded, and degraded by the cell pattern. A 2002 trafficking study44 2002 trafficking study
Rathz DA et al. Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol, 2002 found that the Ser49 receptor exists partially as a highly glycosylated ~105 kDa form that is absent in the Gly49 variant. This extra glycosylation protects the receptor from degradation during sustained agonist exposure. After 18 hours of isoproterenol stimulation, the Gly49 receptor lost 24% of its surface density while the Ser49 receptor lost none. When new receptor synthesis was blocked, the Gly49 form showed 55% degradation versus 36% for Ser49 — a substantial difference in receptor turnover rate.

A complementary study55 complementary study
Levin MC et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem, 2002 confirmed that the Gly49 receptor also displays higher constitutive (baseline) activity and more rapid desensitization. Paradoxically, this combination of higher initial signaling with faster shutdown appears to be cardioprotective — the receptor self-limits before sustained catecholamine exposure can drive harmful cardiac remodeling.

The Evidence

Resting Heart Rate: A landmark family study of 1,348 individuals66 landmark family study of 1,348 individuals
Ranade K et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet, 2002 of Chinese and Japanese descent found a clear additive effect: Ser/Ser homozygotes (AA) had a mean resting heart rate of 69.4 bpm, Ser/Gly heterozygotes (AG) 67.7 bpm, and Gly/Gly homozygotes (GG) 64.2 bpm — a 5.2 bpm gradient (p = 0.0004). The effect size was comparable to beta-blocker therapy, meaning Gly49 homozygotes have a built-in physiological equivalent of low-dose beta-blockade.

Heart Failure Prognosis: The Gly49 allele consistently predicts better heart failure outcomes. A Swedish study of 184 patients77 Swedish study of 184 patients
Borjesson M et al. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J, 2000 found that at 5-year follow-up, 62% of Ser49 homozygotes had died or been hospitalized versus only 39% of Gly49 carriers (HR 2.34 for Ser49, p = 0.003). A Brazilian cohort of 178 patients88 Brazilian cohort of 178 patients
Albuquerque FN et al. Ser49Gly beta1-adrenergic receptor genetic polymorphism as a death predictor in Brazilian patients with heart failure. Arq Bras Cardiol, 2020 confirmed the finding: the Gly49 allele reduced death risk by 63% (OR 0.37, p = 0.03).

However, the Ser49 genotype paradoxically predicts stronger LVEF recovery. A study of 98 HF patients99 study of 98 HF patients
Luzum JA et al. Association of genetic polymorphisms in the beta-1 adrenergic receptor with recovery of left ventricular ejection fraction in patients with heart failure. J Cardiovasc Transl Res, 2019 found that Ser49 homozygosity was the strongest predictor of LVEF recovery (OR 8.2, 95% CI 2.1-32.9, p = 0.003), independent of beta-blocker use. This likely reflects the Ser49 receptor's resistance to downregulation — it maintains signaling capacity that supports contractile recovery when the failing heart is therapeutically managed.

Endurance Performance: A Polish study of 223 athletes and 354 controls1010 Polish study of 223 athletes and 354 controls
Sawczuk M et al. Ser49Gly and Arg389Gly polymorphisms of the ADRB1 gene and endurance performance. Cent Eur J Biol, 2013 found that the Gly49 allele frequency was significantly higher in endurance athletes than controls (11% vs 6.4%, p = 0.026), with an odds ratio of 2.0 (95% CI 1.16-3.47, p = 0.018) for endurance athlete status. Notably, the Gly49:Arg389 haplotype (combining both ADRB1 variants) was also overrepresented among endurance athletes (p = 0.048), suggesting the two variants interact functionally.

Practical Implications

The Ser49Gly variant creates a clinically relevant spectrum: Ser49 homozygotes (AA) have higher resting heart rates, more sustained adrenergic signaling, and greater beta-blocker responsiveness. Gly49 carriers (AG, GG) have intrinsic cardioprotection through enhanced receptor downregulation, lower resting heart rates, and an endurance advantage — but may respond less dramatically to beta-blocker therapy since their receptors already self-regulate.

For heart failure management, both variants matter: Ser49 homozygotes benefit most from aggressive beta-blocker titration (the receptors need pharmacological help to downregulate), while Gly49 carriers have better natural prognosis regardless of treatment.

Interactions

ADRB1 Ser49Gly interacts with Arg389Gly (rs1801253) to form functionally distinct haplotypes. The Ser49/Arg389 combination produces the highest-activity receptor — resistant to downregulation (Ser49) and maximally coupled to G-protein signaling (Arg389). This haplotype may identify individuals with the strongest catecholamine drive and greatest potential benefit from beta-blocker therapy.

The Gly49/Arg389 haplotype was specifically overrepresented among endurance athletes (Sawczuk et al. 2013), combining the enhanced receptor downregulation of Gly49 with the higher coupling efficiency of Arg389 — a profile that may optimize cardiac performance under sustained exercise by providing both strong initial response and effective self-regulation.

Parvez et al. (2012) demonstrated haplotype-level effects in atrial fibrillation rate control: patients with the Ser49/Gly389 haplotype had the best response to rate-control medications (67% responders vs ~50% for other haplotype groups, p < 0.001).

Drug Interactions

metoprolol dose_adjustment literature
bisoprolol dose_adjustment literature
carvedilol dose_adjustment literature

Genotype Interpretations

What each possible genotype means for this variant.

GG Gly49 Homozygote — Enhanced Downregulation Beneficial

Two copies of Gly49 — lowest resting heart rate with built-in cardioprotection and endurance advantage

Your Gly49 receptors lack the highly glycosylated ~105 kDa form that protects Ser49 receptors from degradation. Under sustained catecholamine exposure, your receptors are pulled off the cell surface and degraded efficiently — a 24% loss at 18 hours versus zero for Ser49 (Rathz et al. 2002). With synthesis blocked, the difference widens to 55% vs 36% degradation.

Levin et al. (2002) showed the Gly49 receptor also has higher constitutive activity paired with more rapid desensitization — a "signal and reset" pattern that prevents the sustained, harmful catecholamine signaling that drives cardiac remodeling in heart failure. This likely explains the consistent survival benefit across multiple cohorts: 39% vs 62% event rate (Borjesson 2000), 63% mortality reduction (Albuquerque 2020).

The endurance performance advantage (Sawczuk et al. 2013) may reflect this self-regulatory capacity: during prolonged exercise, your receptors cycle efficiently between active and internalized states, preventing the desensitization fatigue that Ser49 carriers experience while maintaining cardiac output through rapid receptor recycling.

AG Ser/Gly Heterozygote — Intermediate Regulation Intermediate

One Gly49 allele — intermediate receptor downregulation with partial cardioprotection

As a heterozygote, your cardiac cells produce both Ser49 and Gly49 receptor variants. The net effect on receptor dynamics is intermediate: some receptors resist downregulation (Ser49) while others are degraded more rapidly (Gly49). Ranade et al. (2002) confirmed the additive model, with AG heart rates falling precisely between the two homozygous groups (p = 0.0004 for the genotype trend).

In the Borjesson et al. (2000) and Albuquerque et al. (2020) heart failure studies, Gly49 carriers (AG and GG combined) showed significantly better outcomes than Ser49 homozygotes. Your single Gly49 allele provides partial cardioprotection through enhanced receptor turnover of roughly half your receptor population.

For endurance performance, the Gly49 allele was overrepresented among elite endurance athletes (OR 2.0, Sawczuk et al. 2013). Your heterozygous status places you in the favorable end of the population distribution for sustained aerobic performance.

AA Ser49 Homozygote — Sustained Signaling High

Two copies of Ser49 — higher resting heart rate with sustained adrenergic receptor signaling

The Ser49 receptor retains a highly glycosylated ~105 kDa form that resists degradation during sustained agonist exposure (Rathz et al. 2002). After 18 hours of isoproterenol stimulation, Ser49 receptors showed zero loss of surface density, compared to 24% loss for Gly49. This persistent receptor presence means your cardiac cells maintain full catecholamine responsiveness even during prolonged stress or exercise — which drives higher heart rates at rest and during sympathetic activation.

In the Luzum et al. (2019) heart failure cohort, Ser49 homozygosity predicted LVEF recovery with an OR of 8.2 (95% CI 2.1-32.9). This likely reflects the sustained signaling capacity of the receptor — when heart failure is treated appropriately, the maintained receptor density supports contractile recovery. However, without treatment, the same persistent signaling drives adverse remodeling: Borjesson et al. (2000) found Ser49 homozygotes had 62% death/hospitalization at 5 years versus 39% for Gly49 carriers (HR 2.34, p = 0.003).

The Albuquerque et al. (2020) Brazilian cohort confirmed this: the Gly49 allele conferred a 63% mortality reduction (OR 0.37), meaning AA individuals lack this intrinsic cardioprotection.